reports
- Carole Braudeau
- Carole Braudeau
- Luis de Toledo Heras
- Thomas Zlowodzki
- Luis de Toledo Heras
- Thomas Zlowodzki
- Robert Jan Vos
- ING Helpdesk
Benelux Morning Notes
ABN AMRO: 3Q may still support shares to CMD. Aedifica: €13m investment in the Netherlands. Basic-Fit: Strong 3Q25 results; beat on membership ingrowth, on track to reiterated FY25. BE Semiconductor Industries: 3Q25 Preview, order intake is key. IMCD: Acquisition of Dong Yang FT. RELX: Preview 9M25. Signify: 3Q25 preview, more back-end loaded. Staffing: Manpower 3Q25 in line on better revenue trend, 4Q25 outlook cautious. WDP: Results in line, guidance reconfirmed
- Lynn Hautekeete
Basic-Fit 3Q25 trading update: total members already ahead of FY25 CSS
This morning, Basic-Fit published its 3Q25 trading update, showing strong Q3 member growth of +218k vs +110k last year (+95% YoY), despite a -54% YoY decline in club openings. Total members reached 4.73m, already ahead of the FY25 CSS target of 4.64m and our 4.69m (street high). At this pace, 4.8m by year-end looks achievable (+50k in 4Q24). Revenue was in line at €1.034bn vs €1.024bn KBCSe (+16% YoY), but average revenue per member came in soft at €24.60 (-0.5% QoQ). While flattish yield in hig...
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Thibault Leneeuw
- Wim Lewi
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2...
argenx to Highlight Key Data and Breadth of Immunology Innovation at 2025 AANEM Annual Meeting and MGFA Scientific Session Pivotal ADAPT SERON results and interim ADAPT Jr data showcase VYVGART’s potential to treat broad set of myasthenia gravis patientsReal-world evidence and long-term data reinforce VYVGART’s sustained impact on patient outcomesMore than 40 abstracts across MG, CIDP, MMN, and IIM highlight depth of clinical evidence and ongoing commitment to rare neuromuscular disease communities October 15, 2025, 7:00 AM CEST Amsterdam, the Netherlands – argenx SE (Euronext & Nasda...
JDE Peet’s unveils transformed Innovation Laboratory in Utrecht to ac...
JDE Peet’s unveils transformed Innovation Laboratory in Utrecht to accelerate next-generation coffee breakthroughs PRESS RELEASE Amsterdam, October 14, 2025 JDE Peet’s (EURONEXT: JDEP) today announces the opening of its fully revamped modular Innovation Laboratory in Utrecht, the Netherlands, to accelerate next-generation coffee breakthroughs.The new facility underscores the company’s commitment to the rapid scaling of customer-led innovations, as well as the strategic importance of JDE Peet’s global R&D centre in Utrecht. The Innovation Lab’s pioneering, modular setup enables ...
- Jacob Mekhael
Onward Medical Preliminary 3Q25 update shows ARC-EX US commercialisati...
Onward reported a preliminary 3Q25 update, which shows that ARC-EX commercialisation in the US remains on track. With 40 ARC-EX systems sold in the US in 3Q25 (20 systems in 2Q25), we believe FY25 consensus of 150 devices is within reach if this rate of uptake continues for the remainder of the year. Looking ahead, the company previously guided it anticipates home use label expansion for ARC-EX in the US, and plans to initiate the pivotal Empower BP trial of the implantable ARC-IM system in SCI ...
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Thomas Couvreur
- Wim Lewi
ONWARD Medical Provides Preliminary Q3 2025 Update Highlighting Accele...
ONWARD Medical Provides Preliminary Q3 2025 Update Highlighting Accelerating ARC-EX Adoption in the United States EINDHOVEN, the Netherlands, Oct. 13, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces the following key achievements in the third quarter of 2025: Commercial traction: 40 ARC-EX® Systems were sold in Q3, demonstrating continued strong commercial traction...
- Baptiste Salaville
- Roy Külter
- Steven Boumans
- Baptiste Salaville
- Jean-François Granjon
- Robert Jan Vos
- ING Helpdesk
Benelux Morning Notes
Ahold Delhaize: 3Q25 preview - USD headwind to take centre stage. Basic-Fit: 3Q25 results preview, new consensus, we expect strong membership ingrowth. Fagron: 3Q25 growth hiccup in N America, strong organic performance in EMEA, Latam. Lotus Bakeries: UK VAT conflict for Näkd negatively impacts 2024 profitability. Ontex: 3Q25 preview: consensus implies a second profit warning for FY25F. Randstad: Preview 3Q25F results due 22 October; consensus released. Staffing: French revenue impro...
- ING Helpdesk
Benelux Morning Notes
Ageas: AG Real Estate looking to reduce exposure to Interparking, lower capital charges. Air France-KLM: 3Q25 a bit light? ASML: Preview 3Q25, riding the AI wave. Barco: Preview 3Q25, self-help offsets macro headwind. D'Ieteren: Belron starts to roll out static mobile recalibration. Euronext: September's seasonal recovery. Tessenderlo More focus on capital allocation and returns. TomTom: Preview 3Q25, Cost cutting offsets slow markets. Umicore: Gold inventory sale-and-lease-back
- Kristof Samoy
- Wim Hoste
Portzamparc – BNP Paribas Group Initiates Coverage of ONWARD Medical w...
Portzamparc – BNP Paribas Group Initiates Coverage of ONWARD Medical with a Buy Rating and Target Price of EUR 10.20 EINDHOVEN, the Netherlands, Oct. 08, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announces that BNP Paribas’ broker Portzamparc has initiated coverage with a Buy rating and a Target Price of EUR 10.20. Dave Marver, Chief Executive Officer of ONWARD Medical...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.